An Open-Label, First-in-Human Study of the Safety, Tolerability, and Pharmacokinetics of VX-970 in Combination with Either Gemcitabine or Cisplatin and Etoposide in Subjects with Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 15 Nov 2016
At a glance
- Drugs M 6620 (Primary) ; Cisplatin; Etoposide; Gemcitabine
- Indications Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Vertex Pharmaceuticals
- 07 Jun 2017 Biomarkers information updated
- 03 Oct 2016 Planned End Date changed from 1 May 2017 to 1 Jul 2017.
- 03 Oct 2016 Planned primary completion date changed from 1 May 2017 to 1 Jul 2017.